Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies

March 13, 2025 By BioInformant Team Leave a Comment

New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases

CAMBRIDGE, Mass., March 04, 2025 — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company. [Read more…]

Coeptis Therapeutics to Pursue Phase 2 Program Using Allogeneic Cord-Blood Derived NK Cell Therapy

March 13, 2025 By Cade Hildreth, Founder & President Leave a Comment

Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death

DVX201 is the world’s first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ hematopoietic stem and progenitor cells (HSPC) cells.

WEXFORD, PA, Feb 7, 2024 — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the “tripledemic” of influenza, COVID-19 and respiratory syncytial virus (RSV). [Read more…]

Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development

February 17, 2025 By Cade Hildreth, Founder & President Leave a Comment

MONT-SAINT-GUIBERT, Belgium — Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of its Allo Chassis™—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cell primary cells. These innovative cell lines represent a substantial leap forward in cell line development, effectively reducing both timelines and costs. Leveraging Cellistic’s extensive expertise in iPSCs, including in the development of T-cell based treatments, the Allo Chassis™ cell lines set a new standard in the cell therapy market with their unprecedented technology, developed in accordance with current Good Manufacturing Practice (cGMP) standards. [Read more…]

Cook MyoSite Announces Completion of Enrollment for the CELLEBRATE Study

February 12, 2025 By Cade Hildreth, Founder & President Leave a Comment

Pittsburgh, Pa., February 12, 2025 — Cook MyoSite today announced the completion of enrollment of the CELLEBRATE Study, a Phase III clinical trial evaluating the efficacy and safety of iltamiocel compared to a placebo in the reduction of stress incontinence episode frequency in adult female participants with persistent or recurrent stress urinary incontinence (SUI) despite previous surgical treatment. This milestone builds upon the significance of iltamiocel receiving the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) which recognized the seriousness of this unmet need. [Read more…]

NecstGen Partners with Galapagos to Advance Decentralised CAR-T Cell Manufacturing in Europe

February 10, 2025 By Cade Hildreth, Founder & President Leave a Comment

Leiden, Netherlands, 10th February 2025 – NecstGen, a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Cell and Gene Therapies, is proud to announce a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a biotechnology company with operations in Europe and the U.S. to support decentralized manufacturing of Galapagos’ candidate cell therapy products. The partnership underscores both NecstGen’s and Galapagos’ commitment to advancing innovative therapies and bridging the gap between the translation of research, to large clinical trials, and bring products to patients. [Read more…]